| | Sec. 15. 7 MRSA §459, first ¶, as enacted by PL 1981, c. 139, is | amended to read: |
|
| | If any a licensee fails to make such payment as provided in | section 457, subsection 1, paragraph B, that licensee, by reason | of the nonpayment is in default as to all producers or licensees | whose accounts then remain unpaid and the bond provided for shall | must be forfeited to the extent of all sums then due from the | licensee to the producers or licensees. Whenever the commissioner | determines that a licensee has failed to make payment, he the | commissioner shall provide notice, in a manner consistent with | the rule-making provisions of the Maine Administrative Procedure | Act, provide notice that payment under the bond will be sought | and indicating the time within which other producer or licensee | claims may be made known to him the commissioner. Upon | determination of the commissioner that there has been a default | in payment by a licensee, the conditions of the bond shall be are | deemed to be broken and the commissioner may bring action on the | defaulted bond for the benefit of producers or licensees. | Whenever the amount of the bond is not sufficient to cover all | valid claims, the commissioner shall distribute the amount | available on a pro rata basis. |
|
| | Sec. 16. 7 MRSA §481 is repealed. |
|
| | Sec. 17. 7 MRSA §482, first ¶ is amended to read: |
|
| | No A person shall may not manufacture, sell, distribute, | transport, offer or expose for sale, distribution or | transportation any article of commercial feeding stuff, | commercial fertilizer, drug or food which that is adulterated or | misbranded within the meaning of this Title chapter or chapter | 103. |
|
| | Sec. 18. 7 MRSA §483 is amended to read: |
|
| | For the purpose of this Title an article shall be deemed to be | adulterated chapter and chapter 103, unless the term is more | specifically defined, "adulterated" means made impure or inferior | by adding extraneous ingredients:. |
|
| | 1. Drug. In case of a drug: |
|
| A. If, when a drug is sold under or by a name recognized in the | United States pharmacopoeia or national formulary, it differs | from the standard of strength, quality or purity as laid down in | the United States pharmacopoeia or national formulary official at | the time of investigation, or as fixed |
|
|